E-viri
Recenzirano
Odprti dostop
-
Uchida, Yasuhiro; Koyama, Daisuke; Manabe, Kazuya; Suzuki, Kengo; Asano, Naomi; Endo, Mamiko; Fukatsu, Masahiko; Sano, Takahiro; Hayashi, Kiyohito; Takano, Motoki; Takahashi, Hiroshi; Kimura, Satoshi; Ikezoe, Takayuki
Internal Medicine, 2024-Mar-01, Letnik: 63, Številka: 5Journal Article
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR::ABL1 tyrosine kinase. Tyrosine kinase inhibitors (TKIs) have been established as standard therapies for CML. However, some CML patients experience TKI intolerance. Asciminib was approved for CML patients either intolerant or refractory to TKI therapy. We herein report a 63-year-old CML patient who underwent renal transplantation and exhibited TKI intolerance. He was switched to asciminib, which achieved a deep molecular response without exacerbation of the renal function. Our experience revealed that asciminib is effective and safe for CML patients complicated with chronic kidney disease.
